Investor Profile: Kinnevik — Thesis, Cheque Size & How to Apply

Kinnevik is one of Europe's most distinctive growth investors: a Stockholm-listed investment company founded in 1936 that backs challenger technology businesses with patient capital from its own balance sheet. Unlike a traditional venture fund, it raises no closed-end funds; it invests as a long-term active owner across multiple stages of growth. For founders, it offers an investor whose horizon is measured in decades, not fund cycles.

Thesis

Kinnevik describes itself as a leading growth investor, active owner and operational partner providing patient capital to challenger technology-enabled businesses in Europe and the US. Its stated mission is to redefine industries and create remarkable growth companies whose founders are building tomorrow's leaders within healthcare, software and climate. The firm invests at all stages of a company's growth journey, always determined to create long-term value. That breadth lets it back a company early and keep funding it as it scales.

Sectors & Stages

The portfolio is organised around three themes: Health & Bio, Software and Emerging Companies. Within healthcare, it backs digital health and life-science platforms; within software, it focuses on business software and consumer technology; and its emerging-companies bucket covers earlier bets that are still proving their models. It concentrates on Europe and the US, investing from early growth rounds to large late-stage positions.

Fund & Cheque Size

Kinnevik does not publish a closed fund size, and its cheque size is not publicly disclosed. Because it is a listed investment company, its firepower comes from its own balance sheet rather than from a fund it must return within a fixed period. Its interim report for the third quarter of 2026 shows a concentrated portfolio of roughly 20 larger investments, with its biggest positions held in Spring Health, Perk, Enveda and Mews. Founders should therefore judge Kinnevik as a balance-sheet investor, not by fund size.

Notable Portfolio

Among its largest holdings, Spring Health is a mental-health platform in which Kinnevik holds around 12%, and Mews is a hospitality software company in which it holds around 10%. Pleo, the business-spending platform, and Perk are also core software holdings, with stakes of around 13% each. In health, Enveda and Cityblock anchor the portfolio, alongside Oviva, a digital diet and diabetes-care provider in which it holds around 13%. Earlier holdings included Betterment, HungryPanda, Instabee and Omio.

Partners & Programs

Kinnevik was founded in 1936 by the Stenbeck, Klingspor and von Horn families, and its shares are listed on Nasdaq Stockholm under the tickers KINV A and KINV B. It does not run an accelerator or an open application programme. Instead, its model is active ownership: a small investment team works closely with portfolio leadership on strategy, hiring and follow-on financing. For founders, the value lies in that continuity.

How to apply for funding

Kinnevik does not run an open funding application portal. Founders typically approach its investment team directly through the contact routes published on kinnevik.com, ideally with a warm introduction from a portfolio founder, co-investor or adviser. A pitch needs to show a credible path to category leadership in healthcare, software or climate.